At a glance
ClinicalIndex Comparison RecordN/ACompleted· 228 enrolled
Drug / intervention
Adrenocorticotropic hormonedrug
Likely dose
Adrenocorticotropic hormone 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism The ADOPA Randomized Clinical Trial
In Brief
A clinical study evaluating Adrenocorticotropic hormone for Primary Aldosteronism. Completed, enrolled 228 participants across 1 site.
Detailed Summary
To compare the effect of different procedures of AVS(with or without ACTH stimulation) on the long-term outcomes of patients with PA
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Aldosteronism
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartJul 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartJul 8, 2020
Primary CompletionFeb 20, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.0 years ago
Interventions
Adrenocorticotropic hormonedrug
Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.